According to a report in the Wall Street Journal, FDA officials are in a tussle over angiotensin-receptor blockers (ARBs). Based on evidence of an increased risk in cancer, one reviewer argues for a stronger warning but his bosses aren’t convinced. They describe such action as a diversion from assessing new drug applications.

Newport Beach-based nonprofit Coalition Duchenne has awarded a $150,000 grant to a Cedars-Sinai Heart Institute team investigating whether an experimental cardiac stem cell treatment could be used to treat Duchenne muscular dystrophy patients who have developed heart disease.

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review, the New Drug Application (NDA) for PA32540/PA8140.

Cedars-Sinai Heart Institute is honoring the physician widely known as  the leading pioneer in modern mitral heart valve repair, Alain Carpentier, MD, PhD, with the second annual Eliot Corday, MD, International Prize in Heart Research. The Cedars-Sinai Heart Institute established the Corday Prize to recognize physicians and scientists conducting groundbreaking research, or individuals who significantly advance the practice of heart medicine.

The delayed healing of the coronary artery following physicians’ use of drug eluting stents (DES), which increases patients’ risks of developing thrombosis, is a top concern today of interventional cardiologists, according to the results of a survey announced at EuroPCR 2013 in Paris.

The Billings Gazette in Montana is keeping tabs on a $13.5 million expansion and renovation of surgical facilities at the Billings Clinic. The latest update includes a 3-D illustration of the cardiovascular operating room viewed from various angles.

Vincent L. Gott, MD, professor emeritus at Johns Hopkins Heart & Vascular Institute in Baltimore, shares his experiences as a developer of the pacemaker in an interview with CNN. The feature is part of CNN’s “Life Works” series.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Thomas M. Abate, the company's chief financial officer, plans to retire later this year. Abate, who turns 60 in August, plans to remain CFO until his successor is in place. The company has retained Peter Crist of Crist/Kolder Associates to assist in the CFO search.